Your product deserves Italy.
Don't let budget be
the reason it doesn't.
CCi now offers a fully integrated service — strategy, execution and finance at the same table. For companies where the Italian market entry plan is solid but the capital to execute it is the missing piece, we connect you to dedicated funding solutions through a leading international financial partner.
This solution is right for you if:
You have a viable Italian market entry plan but lack the capital to execute it fully
Your HQ has approved the strategy but has not allocated sufficient budget for the commercial build
You are a startup or scale-up with a strong product and limited runway to wait for market returns
You need to prove the Italian market quickly to unlock further investment from your investors
Traditional financing routes are not suited to the specific nature of a MedTech market entry
The right product, the right market, the right moment — but not enough capital to move.
Over the past few years, CCi has heard the same sentence repeatedly: "We want to enter Italy. We have the product. We have the strategy. But we don't have the budget to do it properly."
This is not a rare situation. Building a commercial infrastructure in Italy — distributor contracts, KOL engagement, SSN procurement preparation, field execution — requires sustained investment before revenue begins to return. For many international companies, particularly startups and scale-ups, that investment gap is the single obstacle standing between a viable plan and actual market entry.
"Companies with the right product at the right moment get stuck in front of a financial obstacle that, with the right tools, could be overcome."
This is why CCi added a financial advisory dimension to its offering in 2025 — to remove the last obstacle for companies that have everything in place except the capital to execute.
The investment gap
Italian market entry requires 12–18 months of investment before SSN contracts begin to generate meaningful revenue. Most companies underestimate this timeline and run out of runway before reaching profitability.
HQ budget constraints
International headquarters often approve an Italian strategy but allocate insufficient budget — expecting the market to "pay for itself" from the start. It rarely does, and the underfunded entry fails.
Investor expectations
For VC-backed companies, proving the Italian market is often a condition for the next funding round — but proving it requires investment that the current round doesn't cover. A circular problem that dedicated funding can break.
Wrong financing instruments
Standard business loans or credit facilities are often poorly suited to the specific profile of a MedTech market entry — long investment horizon, limited initial collateral, sector-specific risk profile. Dedicated solutions are designed for exactly this context.
Strategy, execution and finance — integrated in a single engagement.
The Market Entry Funding service adds a financial advisory layer to CCi's existing commercial expertise. Rather than managing strategy and funding separately — with all the misalignments that creates — both are designed and executed together, with CCi coordinating across all three dimensions.
Commercial strategy
The full CCi market entry approach — market assessment, distributor selection, KOL mapping, SSN procurement strategy, commercial planning. The strategic foundation for the entire engagement.
Field execution
Hands-on implementation of the commercial strategy — distributor management, KOL engagement, procurement activity, sales team support and direct HQ reporting. Accountability to results.
Market entry funding
Access to dedicated financing solutions through a leading international financial partner — structured specifically for MedTech market entry, with timelines and terms aligned to the commercial plan.
"A fully integrated engagement: strategy and execution designed together with the capital to deliver them — without the misalignment of managing three separate providers."
Strategy + execution + financeFour steps from assessment to funded execution.
Financial assessment
CCi assesses your company's financial situation — current capital position, investment horizon, projected cash flow and the funding gap between your current resources and the capital required to execute the Italian market entry plan properly.
Funding options
Based on the assessment, CCi identifies the most appropriate funding solutions — structured specifically for MedTech market entry, with terms and timelines aligned to the realities of the Italian commercial cycle.
Financial partner management
CCi manages the relationship with the financial partner — coordinating the documentation, structuring the proposal and ensuring that the financial terms are aligned with the commercial plan rather than working against it.
Integrated execution
With funding secured, CCi executes the commercial plan — strategy, field execution and financial management coordinated from the same table, with full visibility for your HQ on both commercial and financial performance.
Strategy and finance designed together — not bolted together after the fact.
No misalignment between plan and capital
When commercial strategy and financing are managed separately, the financial terms rarely fit the commercial reality — repayment schedules that conflict with cash flow timelines, capital tranches that don't match market entry phases. CCi designs both together, so they reinforce rather than undermine each other.
One point of accountability
With strategy, execution and finance coordinated by CCi, there is a single point of accountability for the entire Italian market entry — commercial performance, financial management and HQ reporting all flow through the same engagement.
Speed to market
Identifying and structuring funding in parallel with commercial planning — rather than sequentially — removes the typical 3–6 month delay between strategy approval and commercial activity. You enter the market sooner, and with the right resources from day one.
An exploratory call commits no one — but it might open doors you didn't know existed.
The financial advisory service is new and deliberately kept confidential in its specific structure until an initial conversation has taken place. CCi does not publicly disclose the name of the financial partner or the specific instruments available — these are discussed directly in the context of each company's situation. What we can say is that the partner is a leading international financial group with specific experience in MedTech and healthcare market entry financing. If budget is part of your Italian market challenge, it is worth a conversation before you assume it is an obstacle.
From colleagues and clients
"Clodio is both a great General Manager and a great person. He has a strong vision about the High Tech and Life Saving Medical Healthcare field derived from more than twenty years old working experience. He has a strong track record for building the business in new geographies and creating development opportunities."
"Clodio is a very pro active manager who it has been a pleasure to work with over recent years. His approach to job situations has been to listen and then act. This is so important when dealing with companies with differing needs in different countries. Clodio is a great team builder with a special focus on objectives and goals."
If budget is part of your Italian market challenge, let's talk before you assume it's an obstacle.
An exploratory call is enough to understand your situation and tell you whether the Market Entry Funding service is a fit — and what it could make possible for your Italian entry.
Schedule a free 30-min call